Searching for your content...
In-Language News
Contact Us
888-776-0942 from 8 AM - 10 PM ET
PTC Therapeutics, Inc. (NASDAQ: PTCT) today reported topline results from the MOVE-FA trial of vatiquinone in patients with Friedreich ataxia. The...
PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today the discontinuation of preclinical and early research programs in gene therapy as part of a...
A PTC Therapeutics, Inc. (NASDAQ: PTCT) anunciou hoje que o desfecho primário foi alcançado no estudo clínico APHENITY de Fase 3, direcionado para o...
PTC Therapeutics, Inc. (NASDAQ: PTCT) anunció hoy que se logró el criterio de valoración primario en el ensayo clínico fase 3, APHENITY, dirigido al...
PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the primary endpoint was achieved in the APHENITY, Phase 3 registration-directed clinical...
PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on April 24, 2023, the company approved non-statutory stock options to purchase an...
PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced a corporate update and financial results for the first quarter ending March 31, 2023. "We are...
PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will host a webcast conference call to report its first quarter 2023 financial ...
PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on March 22, 2023, the company approved non-statutory stock options to purchase an...
PTC Therapeutics, Inc. (NASDAQ: PTCT). Stuart Peltz, Ph.D., founding Chief Executive Officer (CEO) of PTC Therapeutics announced today that he is...
PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced a corporate update and financial results for the fourth quarter and full year ending December...
PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will present a company overview at the following conferences: Raymond James...
PTC Therapeutics, Inc. (NASDAQ: PTCT) anunciou hoje o lançamento do nono programa anual de prêmios STRIVE ™. Por meio desse programa, a PTC concede...
PTC Therapeutics, Inc. (NASDAQ: PTCT) anunció hoy el lanzamiento del noveno programa anual de premios STRIVE ™. A través de este programa, PTC otorga ...
PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will host a webcast conference call to report its fourth quarter and full year ...
PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company has been named the winner of 2023 EURORDIS Black Pearl Company Award for...
PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will present a company overview at the following conference: SVB Securities...
PTC Therapeutics, Inc. (NASDAQ: PTCT) anunciou hoje que o National Institute for Health and Care Excellence (NICE) publicou um Documento de Avaliação ...
PTC Therapeutics, Inc. (NASDAQ: PTCT) anunció hoy que el National Institute for Health and Care Excellence (NICE) ha publicado un documento de...
PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the National Institute for Health and Care Excellence (NICE) has issued a Final Evaluation ...
PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the launch of the ninth annual STRIVE™ awards program. Through this program, PTC awards grants...
PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on Jan. 5, 2023, the company approved non-statutory stock options to purchase an aggregate ...
PTC Therapeutics, Inc. (NASDAQ: PTCT) will present an update on its commercial progress and R&D pipeline at the 41st Annual J.P. Morgan Healthcare...
PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will present a company overview at the 41st Annual J.P. Morgan Healthcare...
Join PR Newswire for Journalists to access all of the free services designated to make your job easier.
In need of subject matter experts for your story? Submit a free ProfNet request and find the sources you need.